Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Two-Drug punch finally knock out whipworm in kids?

NCT ID NCT06188715

Disease control Sponsor: Jennifer Keiser Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether combining two drugs—moxidectin and albendazole—works better than albendazole alone for treating whipworm infections in children aged 6 to 12. The trial took place in Tanzania and involved 224 children. Researchers measured how many children were cured and how much the worm egg count dropped after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
moxidectin and albendazole combination
What this could lead to
If it works, this could provide a more effective treatment for whipworm infections in children, reducing the need for repeat dosing.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The combination may not be significantly better than albendazole alone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

224 people

The number who actually took part.

Started

May 2024

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * individuals aged 6-12 years (confirmed by birth certificate or similar document) * having given written informed consent signed by parents/caregivers * being able and willing to provide two stool samples at baseline and at follow-up assessment (14-21 days) * having at least two out of four Kato-Katz slides positive for T. trichiura at baseline * being able and willing to be examined by a study physician before and after treatment Exclusion Criteria: * presence or signs of major systemic illness, e.g. fever (temporal body temperature of \>38.0°C), severe anaemia (haemoglobin level of \<80 g/l) * history of severe acute disease or unmanaged, severe chronic disease (i.e., condition is not as therapeutically controlled as necessary) * use of anthelminthic drugs during study period * known allergy to study medication (i.e., moxidectin or albendazole) * being prescribed or taking concomitantly medication with known contraindications or drug interactions with the study medication * pregnancy (female participants aged 10-12 years) * concurrent participation in other clinical trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ascariasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ancylostomiasis ascariasis Hookworm Infections hookworm infectious disease trichuriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ascariasis Hookworm infections Trichuriasis

Contacts and locations

Locations

  • Public Health Laboratory Ivo de Carneri

    Chake Chake, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.